NEW YORK, April 20, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company
developing innovative medicines and other products for targeting and treating cancer, today announced that data from a prospective
biomarker analysis of a Phase 3 study using Progenics’ automated bone scan index (aBSI) will be presented in an oral session at the
upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from June 2-6, 2017 in Chicago,
Illinois. In addition, a second abstract from a study on translating the Prostate Cancer Working Group (PCWG) criteria into a
biomarker for prostate cancer will be presented in a poster session.
The schedule for the presentations at ASCO is as follows:
Date & Time: Saturday, June 3, 2017, 1:15 PM-4:15 PM
Session Title: Genitourinary (Prostate) Cancer
Session Type: Oral Abstract Presentation
Title: Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic
castration-resistant prostate cancer (CRPC)
Abstract No.: 5006
Date & Time: Monday, June 5, 2017, 1:15 PM-4:15 PM
Session Title: Genitourinary (Prostate) Cancer
Session Type: Poster Session
Title: Translating Prostate Cancer Working Group (PCWG) criteria into a quantitative progression biomarker in
metastatic Castration Resistant Prostate Cancer (mCRPC)
Abstract No.: 5068
About Progenics
Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to target and treat cancer.
The Company's pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2)
PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM), and 3) imaging analysis tools. Progenics' first
commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant
Pharmaceuticals International, Inc.
This press release may contain projections and other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date
of this communication. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan,"
"could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible,"
"potential," "predict," "project," or other similar words, phrases or expressions. Such statements are predictions only, and are
subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties
include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and
collaborations, such as our collaboration with Valeant on the RELISTOR oral formulation and the Phase 3 clinical program for 1404;
our ability to successfully integrate EXINI Diagnostics AB and to develop and commercialize its products; the unpredictability of
the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved
products; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty
revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining
intellectual property rights; possible product safety or efficacy concerns, general business, financial and accounting matters,
litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and
in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing the information
in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to
update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or
otherwise.
Additional information concerning Progenics and its business may be available in press releases or other
public announcements and public filings made after this release. For more information, please visit www.progenics.com. Please follow us on LinkedIn®. Information on or accessed through our website
or social media sites is not included in the company's SEC filings.
(PGNX-F)
Contact: Melissa Downs Investor Relations (646) 975-2533 mdowns@progenics.com
